The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing ...

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...